Clinical trial · Interventional
Dendritic Cell Immunotherapy for the Patients With Pancreatic Cancer
Single-center Trial Evaluating the Safety and Efficacy of MUC-1/WT-1 Peptide or Tumor Lysate-pulsed Dendritic Cell Immunotherapy for the Patients With Pancreatic Cancer
NCT03114631CI-TRIAL-00042037completedPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The trial evaluates the safety and efficacy of MUC-1/WT-1 peptide and/or tumor lysate-pulsed dendritic cell Immunotherapy for the patients with pancreatic cancer
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Dendritic Cells | — | UNRESOLVED | — |
| Pancreatic Neoplasms | Pancreatic Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Dendritic cells pulsed with MUC-1/WT-1 peptides | Biological | — | UNRESOLVED |
| Dendritic cells pulsed with tumor lysate | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Dendritic cells lysate-pulsed group
- description
- Patients treated according to clinical protocols plus autologous dendritic cells, pulsed with tumor lysate
- interventionNames
- Biological: Dendritic cells pulsed with tumor lysate
- type
- NO_INTERVENTION
- label
- Control group
- description
- Patients treated according to clinical protocols
- type
- EXPERIMENTAL
- label
- Dendritic cells peptide-pulsed group
- description
- Patients treated according to clinical protocols plus autologous dendritic cells, pulsed with MUC-1/WT-1 peptides
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * histologically or cytologically confirmed pancreatic cancer (adenocarcinoma); * HLA-A2 expression by tumor cells; * WT-1/MUC-1 expression by tumor cells. Exclusion Criteria: * refuse of patient to participate in the trial; * pregnancy/lactation; * intercurrent severe chronic diseases; * HIV, Hepatites B/C; * active tuberculosis; * alcohol use disorder/drug addiction.
References
Publications (0)
Data not yet available
No reference posted for this study.